DK2989100T3 - Naphthyridin-derivater, der kan anvendes som Alpha-V-Beta-6-integrin-antagonister - Google Patents
Naphthyridin-derivater, der kan anvendes som Alpha-V-Beta-6-integrin-antagonister Download PDFInfo
- Publication number
- DK2989100T3 DK2989100T3 DK14712666.8T DK14712666T DK2989100T3 DK 2989100 T3 DK2989100 T3 DK 2989100T3 DK 14712666 T DK14712666 T DK 14712666T DK 2989100 T3 DK2989100 T3 DK 2989100T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- ethyl
- formula
- mmol
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (23)
1. Forbindelse med formel (I)
5 (!) hvor Ri betegner et hydrogenatom, en methylgruppe eller en ethylgruppe; R2 betegner et hydrogenatom eller et fluorinatom; R3 betegner et hydrogenatom, en methylgruppe eller en ethylgruppe; eller et 10 farmaceutisk acceptabelt salt deraf.
2. Forbindelse med formel (I) ifølge krav 1, hvor Ri betegner en methylgruppe, R2 betegner et hydrogenatom og R3 betegner en methylgruppe; eller et farmaceutisk acceptabelt salt deraf. 15
3. Forbindelse med formel (I) ifølge krav 1, hvor Ri betegner en ethylgruppe, R2 betegner et hydrogenatom og R3 betegner en ethylgruppe; eller et farmaceutisk acceptabelt salt deraf.
4. Forbindelse med formel (I) ifølge krav 1, hvor Ri betegner et hydrogen atom, R2 betegner et hydrogenatom og R3 betegner en methylgruppe; eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse med formel (I) ifølge krav 1. 25
6. Forbindelse med formel (I) ifølge et af kravene 1 til 5 med konfigurationen:
7. Forbindelse med formel (I) ifølge krav 1, som er udvalgt blandt: 3-(3-(3,5-dimethyl-1 /-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-5 1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1 -yl)butansyre; 3-(3-(5-methyl-1 H- pyrazol-1 -yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre; 3-(3-(5-ethyl-3-methyl-1 /-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre; 10 3-(3-(1 /-/-pyrazol-1 -yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre; 3-(3-(3,5-diethyl-1 /-/-pyrazol-1 -yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre; 3-(3-(4-fluor-3,5-dimethyl-1 /-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-15 tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1 -yl)butansyre; 3-(3-(3-methyl-1 /-/-pyrazol-1 -yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre; eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse med formel (I) ifølge krav 1, som er: 3-(3-(3,5-dimethyl-1 /-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1 -yl)butansyre: 25
9. Forbindelse med formel (I) ifølge krav 1, som er (S)-3-(3-(3,5-dimethyl-1/-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butansyre
10. Forbindelse ifølge krav 1, som er 3-(3-(3,5-dimethyl-1 /-/-pyrazol-1-yl)phe- 5 nyl)-4-((F?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1 - yl)butansyrehydrochloridsalt.
11. Forbindelse ifølge krav 1, som er (S)-3-(3-(3,5-dimethyl-1 /-/-pyrazol-1-yl)phenyl)-4-((/:?)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2- 10 yl)ethyl)pyrrolidin-1 -yl)butansyrehydrochloridsalt.
12. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 11 til anvendelse inden for terapi.
13. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 11 til anvendelse ved behandling af en sygdom eller tilstand, for hvilken der angives en civPe-receptorantagonist.
14. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf 20 ifølge et af kravene 1 til 11 til anvendelse ved behandling af en fibrotisk syg dom.
15. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 14, hvor den fibrotiske sygdom er en pulmonær fibro- 25 se.
16. Forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 11 til anvendelse ved behandling af idiopatisk pulmonær fibrose. 30
17. Farmaceutisk sammensætning omfattende en forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 11 og en eller flere farmaceutisk acceptable bærere, fortyndingsmidler eller hjælpestoffer. 5
18. Kombination omfattende en forbindelse med formel (I) eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 11 og mindst et andet farmaceutisk aktivt stof.
19. Kombination ifølge krav 18 til anvendelse inden for terapi.
20. Kombination ifølge krav 18, eller kombination til anvendelse ifølge krav 19. hvor en hæmmer af TGF3-syntese, for eksempel pirfenidon, er det andet farmaceutisk aktive stof. 15
21. Kombination ifølge krav 18, eller kombination til anvendelse ifølge krav 19, hvor nintedanib (BIBF-1120) er det andet farmaceutisk aktive stof.
22. Kombination ifølge krav 18, eller kombination til anvendelse ifølge krav 19, hvor et anti avp6-antistof er det andet farmaceutisk aktive stof.
23. Forbindelse med formel (II)
(Π) 25 hvor Ri betegner et hydrogenatom, en methylgruppe eller en ethylgruppe; R2 betegner et hydrogenatom eller et fluorinatom; R3 betegner et hydrogenatom, en methylgruppe eller en ethylgruppe; og R4 er en Ci- til Ce-alkylgruppe; eller et salt deraf.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1305668.4A GB201305668D0 (en) | 2013-03-28 | 2013-03-28 | Avs6 Integrin Antagonists |
| PCT/EP2014/056013 WO2014154725A1 (en) | 2013-03-28 | 2014-03-26 | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2989100T3 true DK2989100T3 (da) | 2018-04-23 |
Family
ID=48444909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14712666.8T DK2989100T3 (da) | 2013-03-28 | 2014-03-26 | Naphthyridin-derivater, der kan anvendes som Alpha-V-Beta-6-integrin-antagonister |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US10023568B2 (da) |
| EP (2) | EP2989100B1 (da) |
| JP (1) | JP6095847B2 (da) |
| KR (2) | KR101775085B1 (da) |
| CN (1) | CN105189499B (da) |
| AR (1) | AR095768A1 (da) |
| AU (1) | AU2014243068C1 (da) |
| BR (1) | BR112015024530A8 (da) |
| CA (1) | CA2903358A1 (da) |
| CL (1) | CL2015002860A1 (da) |
| CR (1) | CR20150509A (da) |
| CY (1) | CY1120188T1 (da) |
| DK (1) | DK2989100T3 (da) |
| DO (1) | DOP2015000251A (da) |
| EA (1) | EA027305B1 (da) |
| ES (1) | ES2665597T3 (da) |
| GB (1) | GB201305668D0 (da) |
| HR (1) | HRP20180528T1 (da) |
| HU (1) | HUE036750T2 (da) |
| IL (1) | IL241184A0 (da) |
| LT (1) | LT2989100T (da) |
| MA (1) | MA38540B1 (da) |
| ME (1) | ME02987B (da) |
| MX (1) | MX363288B (da) |
| NO (1) | NO2989100T3 (da) |
| NZ (1) | NZ629025A (da) |
| PE (1) | PE20151606A1 (da) |
| PH (1) | PH12015502232B1 (da) |
| PL (1) | PL2989100T3 (da) |
| PT (1) | PT2989100T (da) |
| RS (1) | RS57220B1 (da) |
| SG (1) | SG11201506813QA (da) |
| SI (1) | SI2989100T1 (da) |
| SM (1) | SMT201800247T1 (da) |
| TW (1) | TWI632143B (da) |
| UA (1) | UA114952C2 (da) |
| UY (1) | UY35505A (da) |
| WO (1) | WO2014154725A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3050878T1 (sl) | 2013-09-24 | 2022-01-31 | Fujifilm Corporation | Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te |
| GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| KR20170123315A (ko) | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| GB201615588D0 (en) | 2016-09-14 | 2016-10-26 | Glaxosmithkline Ip Dev Ltd | TSLP Binding Proteins |
| GB201604589D0 (en) * | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| ES2984394T3 (es) | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| WO2018089357A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
| HRP20210228T1 (hr) * | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| AU2017359023B2 (en) | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| KR102700471B1 (ko) | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| FI3761980T3 (fi) | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) * | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020047207A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
| EP4605008A1 (en) * | 2022-12-14 | 2025-08-27 | Alnylam Pharmaceuticals, Inc. | Alpha-v beta-6 integrin ligands for extrahepatic delivery |
| IL321740A (en) * | 2022-12-27 | 2025-08-01 | Pliant Therapeutics Inc | Alpha-V-beta-8 integrin inhibitors and their uses |
| WO2025259747A2 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof |
| WO2025259743A1 (en) | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dual conjugate compounds for extrahepatic delivery |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| CN1589145A (zh) | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| WO2000078317A1 (en) | 1999-06-23 | 2000-12-28 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1229910A4 (en) | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| PL355011A1 (en) * | 1999-11-08 | 2004-03-22 | Merck & Co, Inc. | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
| US7119098B2 (en) | 2000-06-15 | 2006-10-10 | Pharmacia Corporation | Heteroarylakanoic acids as intergrin receptor antagonists |
| AU7793501A (en) | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| CA2432504A1 (en) | 2001-01-03 | 2002-07-11 | Merck & Co., Inc. | Methods and compositions for treating periodontal disease |
| DE10112771A1 (de) | 2001-03-16 | 2002-09-26 | Merck Patent Gmbh | Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| EP1592421A1 (en) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US6932865B2 (en) | 2003-04-11 | 2005-08-23 | Lockheed Martin Corporation | System and method of making single-crystal structures through free-form fabrication techniques |
| CN1901958B (zh) | 2003-11-03 | 2011-03-09 | 葛兰素集团有限公司 | 流体分配装置 |
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
| EP2211615A4 (en) | 2007-10-22 | 2010-10-13 | Glaxosmithkline Llc | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS |
| WO2011111880A1 (ko) | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604589D0 (en) | 2016-03-18 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical compound |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
-
2013
- 2013-03-28 GB GBGB1305668.4A patent/GB201305668D0/en not_active Ceased
-
2014
- 2014-03-26 NO NO14712666A patent/NO2989100T3/no unknown
- 2014-03-26 PT PT147126668T patent/PT2989100T/pt unknown
- 2014-03-26 SI SI201430687T patent/SI2989100T1/en unknown
- 2014-03-26 RS RS20180537A patent/RS57220B1/sr unknown
- 2014-03-26 SM SM20180247T patent/SMT201800247T1/it unknown
- 2014-03-26 AU AU2014243068A patent/AU2014243068C1/en not_active Ceased
- 2014-03-26 US US14/778,095 patent/US10023568B2/en not_active Expired - Fee Related
- 2014-03-26 UA UAA201508518A patent/UA114952C2/uk unknown
- 2014-03-26 JP JP2016504647A patent/JP6095847B2/ja not_active Expired - Fee Related
- 2014-03-26 ES ES14712666.8T patent/ES2665597T3/es active Active
- 2014-03-26 KR KR1020157031064A patent/KR101775085B1/ko not_active Expired - Fee Related
- 2014-03-26 CN CN201480018839.6A patent/CN105189499B/zh not_active Expired - Fee Related
- 2014-03-26 PE PE2015002064A patent/PE20151606A1/es active IP Right Grant
- 2014-03-26 AR ARP140101378A patent/AR095768A1/es unknown
- 2014-03-26 MA MA38540A patent/MA38540B1/fr unknown
- 2014-03-26 KR KR1020177024389A patent/KR102042141B1/ko not_active Expired - Fee Related
- 2014-03-26 DK DK14712666.8T patent/DK2989100T3/da active
- 2014-03-26 NZ NZ629025A patent/NZ629025A/en not_active IP Right Cessation
- 2014-03-26 HR HRP20180528TT patent/HRP20180528T1/hr unknown
- 2014-03-26 ME MEP-2018-83A patent/ME02987B/me unknown
- 2014-03-26 EP EP14712666.8A patent/EP2989100B1/en active Active
- 2014-03-26 UY UY0001035505A patent/UY35505A/es not_active Application Discontinuation
- 2014-03-26 TW TW103111317A patent/TWI632143B/zh not_active IP Right Cessation
- 2014-03-26 WO PCT/EP2014/056013 patent/WO2014154725A1/en not_active Ceased
- 2014-03-26 LT LTEP14712666.8T patent/LT2989100T/lt unknown
- 2014-03-26 CA CA2903358A patent/CA2903358A1/en not_active Abandoned
- 2014-03-26 EP EP18157255.3A patent/EP3360876A1/en not_active Withdrawn
- 2014-03-26 BR BR112015024530A patent/BR112015024530A8/pt not_active IP Right Cessation
- 2014-03-26 EA EA201591503A patent/EA027305B1/ru not_active IP Right Cessation
- 2014-03-26 SG SG11201506813QA patent/SG11201506813QA/en unknown
- 2014-03-26 PL PL14712666T patent/PL2989100T3/pl unknown
- 2014-03-26 HU HUE14712666A patent/HUE036750T2/hu unknown
- 2014-03-26 MX MX2015013742A patent/MX363288B/es unknown
-
2015
- 2015-09-06 IL IL241184A patent/IL241184A0/en active IP Right Grant
- 2015-09-24 PH PH12015502232A patent/PH12015502232B1/en unknown
- 2015-09-25 CL CL2015002860A patent/CL2015002860A1/es unknown
- 2015-09-28 CR CR20150509A patent/CR20150509A/es unknown
- 2015-09-28 DO DO2015000251A patent/DOP2015000251A/es unknown
-
2018
- 2018-05-09 CY CY20181100479T patent/CY1120188T1/el unknown
- 2018-06-13 US US16/007,584 patent/US10450312B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2989100T3 (da) | Naphthyridin-derivater, der kan anvendes som Alpha-V-Beta-6-integrin-antagonister | |
| US10513517B2 (en) | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | |
| JP6672276B2 (ja) | 新規化合物 | |
| JP2019509304A (ja) | インテグリンアンタゴニストとしてのナフチリジン | |
| HK1214262B (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists |